These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 26836245

  • 1. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S.
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA, Archer DF, Kagan R, Bernick B, Graham S, Constantine GD, Mirkin S.
    Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
    Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S.
    Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
    [Abstract] [Full Text] [Related]

  • 6. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
    Liu JH, Bernick B, Mirkin S.
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH.
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [Abstract] [Full Text] [Related]

  • 9. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Gasper G, Graham S, Mirkin S, REJOICE Study Group.
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Physical characteristics and properties of estradiol softgel vaginal inserts.
    Simon JA, Pickar JH, Shadiack AM, Warrier B, Graham S, Bernick B, Mirkin S.
    Menopause; 2020 Feb; 27(2):150-155. PubMed ID: 31663981
    [Abstract] [Full Text] [Related]

  • 12. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA, Derogatis L, Simon JA, Constantine GD, Graham S, Bernick B, Gasper G, Mirkin S.
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [Abstract] [Full Text] [Related]

  • 13. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
    Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, Mirkin S.
    J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
    [Abstract] [Full Text] [Related]

  • 14. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA, Kagan R, Archer DF, Constantine GD, Bernick B, Graham S, Mirkin S.
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F, Caruso S, Di Lorenzo G, Romano F, Mirandola M, Nappi RE.
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G.
    Menopause; 2019 Jan 28; 26(6):611-621. PubMed ID: 30694917
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.
    Kingsberg SA, Kroll R, Goldstein I, Kushner H, Bernick B, Graham S, Mirkin S, Constantine GD.
    Menopause; 2017 Aug 28; 24(8):894-899. PubMed ID: 28195995
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.
    Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, LaCroix AZ, Caan B, Guthrie KA.
    JAMA Intern Med; 2018 May 01; 178(5):681-690. PubMed ID: 29554173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.